Suppr超能文献

单磷酸脂A后的心肌保护:兔心脏延迟抗缺血特性的研究

Myocardial protection after monophosphoryl lipid A: studies of delayed anti-ischaemic properties in rabbit heart.

作者信息

Baxter G F, Goodwin R W, Wright M J, Kerac M, Heads R J, Yellon D M

机构信息

Hatter Institute for Cardiovascular Studies, Division of Cardiology, University College London Hospital and Medical School.

出版信息

Br J Pharmacol. 1996 Apr;117(8):1685-92. doi: 10.1111/j.1476-5381.1996.tb15340.x.

Abstract
  1. Monophosphoryl lipid A (MLA) is a non-pyrogenic derivative of Salmonella lipopolysaccharide. Administration of this agent at high doses to rats and at low doses to dogs was previously shown to confer marked protection against ischaemia-reperfusion 24 h later, although the cellular mechanisms of this delayed protection are obscure. We hypothesized that MLA pretreatment causes the induction of the 70 kDa cytoprotective stress protein HSP70i in the myocardium. If this were the case, protection against ischaemia-reperfusion injury would be observed both in vitro and in vivo. 2. Rabbits were pretreated with MLA 0.035 mg kg-1, i.v. or vehicle solution. For the in vitro study, hearts were isolated 24 h later and Langendorff-perfused with Krebs-Henseleit buffer at 37 degrees C. Global ischaemia was induced for 20 min followed by 120 min reperfusion. Recovery of post-ischaemic left ventricular function and lactate dehydrogenase efflux was similar in MLA and vehicle pretreated hearts and there was no significant difference in the percentage of infarction of the left ventricle determined by triphenyltetrazolium staining (MLA 22.4 +/- 5.2%, vehicle 24.8 +/- 5.1%). 3. When 30 min regional ischaemia and 120 min reperfusion was instituted in pentobarbitone-anaesthetized rabbits 24 h after pretreatment with MLA or vehicle, the percentage infarction within the risk zone was reduced from 42.6 +/- 5.7% in vehicle pretreated animals to 19.6 +/- 4.4% in MLA pretreated animals (P < 0.01). 4. Determination of myocardial HSP70i content by Western blot analysis showed that MLA treatment did not increase HSP70i immunoreactivity. 5. We conclude that MLA at this dose confers protection only against ischaemia-reperfusion injury in vivo and that this protection is not related to induction of HSP70i. Because protection was observed only in vivo it seems possible that the delayed protection conferred by MLA is mediated by effects on humoral or blood-borne factors.
摘要
  1. 单磷酰脂质A(MLA)是沙门氏菌脂多糖的一种无热原衍生物。先前研究表明,给大鼠高剂量以及给狗低剂量注射该制剂,可在24小时后对缺血再灌注产生显著保护作用,尽管这种延迟保护的细胞机制尚不清楚。我们推测,MLA预处理可诱导心肌中70 kDa细胞保护应激蛋白HSP70i的产生。如果是这样,那么在体外和体内都能观察到对缺血再灌注损伤的保护作用。2. 给兔子静脉注射0.035 mg kg-1的MLA或赋形剂溶液进行预处理。在体外研究中,24小时后取出心脏,在37℃用Krebs-Henseleit缓冲液进行Langendorff灌注。诱导全心缺血20分钟,随后再灌注120分钟。MLA预处理组和赋形剂预处理组心脏缺血后左心室功能恢复及乳酸脱氢酶流出情况相似,用三苯基四氮唑染色测定的左心室梗死百分比无显著差异(MLA组为22.4±5.2%,赋形剂组为24.8±5.1%)。3. 在MLA或赋形剂预处理24小时后的戊巴比妥麻醉兔子中,进行30分钟局部缺血和120分钟再灌注,危险区域内的梗死百分比从赋形剂预处理动物的42.6±5.7%降至MLA预处理动物的19.6±4.4%(P<0.01)。4. 通过蛋白质免疫印迹分析测定心肌HSP70i含量,结果显示MLA处理并未增加HSP70i免疫反应性。5. 我们得出结论,该剂量的MLA仅在体内对缺血再灌注损伤具有保护作用,且这种保护作用与HSP70i的诱导无关。由于仅在体内观察到保护作用,因此MLA所赋予的延迟保护作用似乎可能是由对体液或血源性因子的影响介导的。
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89e5/1909552/800095febd27/brjpharm00097-0084-a.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验